Isowater is pleased to see this precedent setting FDA approval in place for Austedo by Teva. It has had the developmental name of SD-809. As it is for the treatment of chorea, which is associated with Huntington’s disease, it offers an improved product to reduce the random involuntary twisting movements that accompany people with Huntington’s. This new deuterated drug will be able to help the quality of daily life for those who currently suffer. Isowater looks forward to a new chapter of drug development and continuing to secure the long-term deuterium supply chain to pharmaceutical firms to create as well as improve pharmaceuticals and importantly the quality of life for others. For more information on how to buy heavy water click here.